{"id":719772,"date":"2026-06-06T21:33:49","date_gmt":"2026-06-06T21:33:49","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/719772\/"},"modified":"2026-06-06T21:33:49","modified_gmt":"2026-06-06T21:33:49","slug":"ilant-health-raises-15m-to-replace-fragmented-obesity-care-with-ai-supported-precision-care","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/719772\/","title":{"rendered":"Ilant Health Raises $15M to Replace Fragmented Obesity Care With AI-supported, Precision Care"},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">NEW YORK&#8211;(<a href=\"https:\/\/www.businesswire.com\" target=\"_blank\" rel=\"nofollow noopener\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ilanthealth.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Ilant&amp;index=1&amp;md5=672226a2208b47a33448ed9cf9d293f1\" shape=\"rect\" target=\"_blank\">Ilant<\/a><a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ilanthealth.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Health&amp;index=2&amp;md5=5e112115cfcec539574fa11ad406e1bd\" shape=\"rect\" target=\"_blank\"> Health<\/a>, the value-based obesity treatment company working with employers and health plans to deliver clinical outcomes and reduce the total cost of care, announced it has raised $15 million in Series A funding, bringing its total funding to over $22M to date. The round was led by <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcornucopiancapital.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Cornucopian+Capital&amp;index=3&amp;md5=18433314ba723efaea5f90a1b903c668\" shape=\"rect\" target=\"_blank\">Cornucopian Capital<\/a>, with participation from <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.naturalx.vc%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=naturalX&amp;index=4&amp;md5=73c93808c091acb7d60b01570b3992b7\" shape=\"rect\" target=\"_blank\">naturalX<\/a>, <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpeakbridge.vc%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Peakbridge&amp;index=5&amp;md5=3c7d13d0507b7e3e81e9cd0c2e9aacf7\" shape=\"rect\" target=\"_blank\">Peakbridge<\/a>, <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.semcap.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Semcap+AI&amp;index=6&amp;md5=e4d62ee4b2d090c7085a3267189ba1a1\" shape=\"rect\" target=\"_blank\">Semcap AI<\/a>, <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevidenced.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Evidenced&amp;index=7&amp;md5=f26c9cf85f8af03cfc6edeec60b6534f\" shape=\"rect\" target=\"_blank\">Evidenced<\/a>, <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.operatorpartners.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Operator+Partners&amp;index=8&amp;md5=a082ea89b4985e3bfdba903e7ca8b167\" shape=\"rect\" target=\"_blank\">Operator Partners<\/a>, as well as existing investors <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.celtic.vc%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Celtic&amp;index=9&amp;md5=1e844f9176ad96f18c8575878f21dc88\" shape=\"rect\" target=\"_blank\">Celtic<\/a>, <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifex.vc%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=LifeX&amp;index=10&amp;md5=2921a6c486d195bbe9447fc35f81ad64\" shape=\"rect\" target=\"_blank\">LifeX<\/a>, and <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alphalab.org%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=AlphaLab&amp;index=11&amp;md5=000af84a7017715a3b1ea946f9b8ecc9\" shape=\"rect\" target=\"_blank\">AlphaLab<\/a>.<\/p>\n<p id=\"pull-quote\" class=\"font-figtree text-lg lg:text-[24px] leading-6 lg:leading-[38px]\">\u201cIlant is applying that model to one of the most important and costly areas in healthcare. The company understands that the future of obesity and cardiometabolic care&#8230;&#8221;<\/p>\n<p><a data-app=\"share_buttons\" data-app-config=\"{&quot;service&quot;:&quot;twitter&quot;, &quot;templates&quot;:{&quot;twitter&quot;:{&quot;body&quot;:&quot;\u201cIlant is applying that model to one of the most important and costly areas in healthcare. The company understands that the future of obesity and cardiometabolic care...\\&quot; ${link}&quot;}}}\" id=\"tweet-pull-quote\" target=\"_blank\">Share<\/a><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nFounded by Elina Onitskansky (formerly McKinsey and Molina Healthcare), Ilant works directly with employers and health plans to deliver comprehensive, clinician-led care for obesity and related conditions. Ilant delivers measurable clinical and financial outcomes, versus solutions focused on access or cost control, or fragmented solutions that look at obesity and weight loss in isolation from broader health.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nEarly results show that members achieve 15% weight loss on average \u2014 well above <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F29401050%2F%23%3A%7E%3Atext%3DConclusion%3A%2520The%2520average%2520weight%2520change%2C5.8%2525%2520weight%2520loss%2520from%2520baseline.&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=5.8%25&amp;index=12&amp;md5=f4a1fa8f165888d950bcbd752d5dd281\" shape=\"rect\" target=\"_blank\">5.8%<\/a> reported in real-world settings &#8211; alongside measurable gains in broader biometrics and overall wellbeing, including an average of two additional mentally healthy days per month. These results highlight Ilant\u2019s success improving outcomes in clinically meaningful ways. The company does this while managing both treatment costs and total cost of care for employers and payers, creating a uniquely compelling value proposition.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nThe Rise of AI-Enabled Healthcare Services and Precision Care<br \/>\n<br \/>The company delivers these results through clinician-led care with treatment that is precision-matched to individual member needs based on clinical, behavioral, and personal data, and continuously optimized based on how each individual responds in practice. Treatment includes behavioral therapy, medication (including both GLP-1 and non-GLP-1 therapies), and surgical options as delivered in a comprehensive model that address nutrition, physical activity, and stress alongside medical care.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nThe approach focuses on initiating with the best treatment, and consistently enhancing outcomes over time, delivering life-changing clinical results while avoiding unnecessary or ineffective care.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nEarly Traction and Demand Signal Rapid growth<br \/>\n<br \/>Ilant is already working with leading employers and healthcare partners to deliver measurable improvements in both outcomes and cost, reflecting strong demand for models that move beyond point solutions toward integrated, outcomes-based care.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n\u201cWhat stood out with Ilant was their precision-based, data-driven approach to obesity care, not a one-size-fits-all model centered on medication only,\u201d said Kenneth L. Gardner, Director of Growth, Benefit Operations, SEIU 775 BENEFITS GROUP. \u201cIlant conducted a detailed analysis of our population and identified the members most likely to benefit clinically and financially, giving us confidence in both improved outcomes and meaningful ROI. Just as importantly, the members consistently share positive feedback about the care, support, and personalized attention they receive from the Ilant team.\u201d<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nAs part of this approach, in November 2025, Ilant announced direct contracting and transparent pricing solutions for obesity management medicines available through <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flilly-employer-connect-platform-launches-over-fifteen&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Lilly&amp;index=13&amp;md5=4f653796763150dd68583eddf70c9fa7\" shape=\"rect\" target=\"_blank\">Lilly<\/a><a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flilly-employer-connect-platform-launches-over-fifteen&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=%26%238217%3Bs+Employer+Connect&amp;index=14&amp;md5=e4f6f7e8a66dc7564b8eca413f43b857\" shape=\"rect\" target=\"_blank\">\u2019s Employer Connect<\/a> program; the company is also working with Novo Nordisk. These manufacturer contracts enable Ilant to provide transparent prices for medications with flexibility in design, giving employers greater visibility and control over one of the fastest-growing areas of healthcare spend.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nRecent results from Eli Lilly and Company, reported by the <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ft.com%2Fcontent%2F527fb779-bc12-436d-a6cc-1ba4dfc9a5f5%3Fsyn-25a6b1a6%3D1&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=Financial+Times&amp;index=15&amp;md5=2f1759337014a46cbbcddfb25fa5dff3\" shape=\"rect\" target=\"_blank\">Financial Times<\/a>, highlight the scale and speed of demand for GLP-1 weight-loss drugs, with revenues surging as adoption accelerates. As more employers face pressure to offer coverage while managing rising pharmacy spend, the need for models and infrastructure that can bring predictability and control &#8211; while delivering outcomes and experience &#8211; has never been higher.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n\u201cEmployers and health plans are facing a real dilemma right now \u2014 they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost,\u201d said Elina Onitskansky, Founder and CEO of Ilant. \u201cThat\u2019s not a sustainable model. If we don\u2019t change how care is delivered, we\u2019re just paying more for the same broken system, and we risk a crisis where both chronic disease and costs are spiraling out of control. Ilant\u2019s model focuses on delivering real value with manageable treatment costs and clinically meaningful care that actually bends the cost curve.\u201d<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nInvestors see this shift as defining the next phase of obesity and cardiometabolic care.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n\u201cWe believe the next generation of category-defining companies will be those that deliver outcomes as a service, not just tools or access,\u201d said Aryeh Ganz, Founder and Managing Partner of Cornucopian Capital. \u201cIlant is applying that model to one of the most important and costly areas in healthcare. The company understands that the future of obesity and cardiometabolic care will not be defined by access to a single class of drugs, but by the ability to deliver the right care to the right patient at the right time. Their model aligns clinical rigor with economic value in a way that we believe will define this category over the next decade.\u201d<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nAbout Ilant Health<br \/>\n<br \/>Ilant Health is an obesity and cardiometabolic health company, focused on increasing access to treatment while reducing total cost of care for employers and payers through value-based care. Ilant Health provides the single front door for individuals with obesity, delivering end-to-end evidence-based solutions (bariatric surgery, medication, intense behavioral therapy) through a technology-enabled and analytics-driven obesity medicine practice. To learn more about Ilant Health, please visit their website at <a rel=\"nofollow noopener\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ilanthealth.com%2F&amp;esheet=54545467&amp;newsitemid=20260602971156&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ilanthealth.com%2F&amp;index=16&amp;md5=72cfa8c10947216217ce406594300583\" shape=\"rect\" target=\"_blank\">https:\/\/www.ilanthealth.com\/<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"NEW YORK&#8211;(BUSINESS WIRE)&#8211;Ilant Health, the value-based obesity treatment company working with employers and health plans to deliver clinical&hellip;\n","protected":false},"author":2,"featured_media":719773,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[49,48,84,392],"class_list":["post-719772","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-ca","tag-canada","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/719772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=719772"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/719772\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/719773"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=719772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=719772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=719772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}